COMPANY OVERVIEW
- HOME
- COMPANY OVERVIEW
History
January 2017: Cell-Axia Inc. was founded in Chuo-ku, Tokyo.
Management Team
Dr.Seki has extensive experience in drug discovery research to the company’s product strategy for the immunology, inflammation, and respiratory diseases area at Mitsubishi Kasei Corporation (now Mitsubishi Tanabe Pharma Corporation). Leveraging a decade of executive leadership at some biotech ventures, he founded our company in 2017. His roles at these ventures included Executive Officer at Anges MG and Oncolys BioPharma and others, where he was responsible for product strategy, regulatory affairs, clinical development, and business development. Dr.Seki holds a Ph.D. from the University of Tokyo and served as a Postdoctoral Research Fellow at Boston Children’s Hospital, Harvard Medical School.
Mr. Shimura was appointed as Outside Director in 2023. He brings extensive investment and corporate management experience, having served in senior roles at IHI Corporation, Yasuda Enterprise Development, NeoStella Capital, Japan Asia Investment, and TEPCO Ventures.
Currently serves as President of Nobilis Corporation and Advisor to Kiraboshi Capital.
Dr. Onishi was appointed as Outside Statutory Auditor in 2023 and became Outside Director in 2024. He offers deep pharmaceutical industry expertise from his career at Meiji Seika Pharma, where he served as R&D Planning & Administration General Manager and Full-time Audit & Supervisory Board Member.
Currently serves as Advisor to Meiji Seika Pharma and Meiji Animal Health.
Dr. Misawa was appointed as Outside Director in 2017. He is a President and Managing Director at Miyako Capital, one of CellAxia Inc.’s key shareholders.
With extensive life sciences research experience and a proven venture capital track record, his career has included positions at Kurume University, University of Shizuoka, and Baylor College of Medicine.
Mr. Hayashi was appointed as Full-time Outside Statutory Auditor in 2026.
He has extensive experience in the telecommunications industry and corporate management within the NTT Group.
Previously served as Director at NTT Town Page and Full-time Statutory Auditor at NTT-ME.
Mr. Kaburagi was appointed as Outside Statutory Auditor in 2022. As a Certified Public Accountant, he provides expertise in finance and accounting.
Following his career at Chuo Shinko Audit Corporation, he established Kaburagi Certified Public Accountant Office.
Dr. Doi was appointed as Outside Statutory Auditor in 2023.
He has extensive drug discovery R&D experience and Statutory Auditor expertise in the pharmaceutical industry.
Previously served as Quality Assurance General Manager and Full-time Statutory Auditor at Kaken Pharmaceutical and currently serves as Full-time Outside Statutory Auditor at Kringle Pharma.
Company Overview
| Company Name | CellAxia Inc. |
|---|---|
| Address | 1-10-9-6F Nihonbashi Horidome-cho, Chuo-ku, Tokyo 103-0012, Japan |
| Phone | +81-3-3527-2448 |
| FAX | +81-3-3527-2449 |
| info@cellaxia.co.jp | |
| Founded | January 2017 |
| Capital | ¥1.645 billion (including capital reserves) |
| Scope of Business | Research, development, manufacturing and sales of pharmaceuticals and regenerative medicine products |
1-10-9-6F Nihonbashi Horidome-cho, Chuo-ku, Tokyo 103-0012, Japan